Regulatory compliance
The TGA monitors and enforces regulatory compliance in relation to therapeutic goods. This supports consumer protection and a fair market for industry.
-
Further examples of counterfeit Ozempic-labelled products have been detected and stopped at the Australian border.
-
Takeda Pharmaceuticals Australia has issued a product alert for Vyvanse capsules due to minor packaging errors. The medication is safe to use as prescribed.
-
Magnum XXL capsules pose a serious risk to your health and should not be taken.
-
Summit Pharmacy Pty Ltd issued infringement notices for the alleged unlawful manufacturing of medicinal cannabis products
We have issued 4 infringement notices totalling $75,120 to Queensland based pharmacy Summit Pharmacy Pty Ltd, for the alleged unlawful manufacturing of medicinal cannabis products. -
Listed medicines requiring a warning statement
We will be initiating targeted compliance reviews of selected listed medicines that are required to display a warning statement -
Enforceable undertaking: Your Solution Compounding Pharmacy
We have accepted a court-enforceable undertaking from Your Solution Compounding Pharmacy Pty Ltd, regarding advertising of prescription-only compounded medicines for weight-loss.
-
Clarifies requirements for SAS and AP applications for healthcare practitioners to access Category 2, 3, 4 and/or 5 (i.e. Schedule 8) medicinal cannabis medicines for their patients under the age of 18 years (paediatric patients).
-
This plan outlines our compliance and education priorities for 2024-2025.
-
This fact sheet is for healthcare practitioners to help understand the rules surrounding importation of cosmetic injectables.